# Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.

> **NCT01618734** · — · COMPLETED · sponsor: **Henri Mondor University Hospital** · enrollment: 50 (actual)

## Conditions studied

- Immune Thrombocytopenia
- Thrombopoietin Receptor Agonist

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01618734
- **Lead sponsor:** Henri Mondor University Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01618734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01618734, "Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01618734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*